These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 34498427)

  • 21. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.
    van Veldhuisen DJ; Ponikowski P; van der Meer P; Metra M; Böhm M; Doletsky A; Voors AA; Macdougall IC; Anker SD; Roubert B; Zakin L; Cohen-Solal A;
    Circulation; 2017 Oct; 136(15):1374-1383. PubMed ID: 28701470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia.
    Basha A; Ibrahim MIM; Hamad A; Chandra P; Omar NE; Abdullah MAJ; Aldapt MB; Hussein RM; Mahfouz A; Adel AA; Shwaylia HM; Ekeibed Y; AbuMousa R; Yassin MA
    PLoS One; 2021; 16(8):e0255104. PubMed ID: 34375369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases.
    Laass MW; Straub S; Chainey S; Virgin G; Cushway T
    BMC Gastroenterol; 2014 Oct; 14():184. PubMed ID: 25326048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous iron and chronic obstructive pulmonary disease: a randomised controlled trial.
    Santer P; McGahey A; Frise MC; Petousi N; Talbot NP; Baskerville R; Bafadhel M; Nickol AH; Robbins PA
    BMJ Open Respir Res; 2020 Jun; 7(1):. PubMed ID: 32565444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease.
    Evstatiev R; Alexeeva O; Bokemeyer B; Chopey I; Felder M; Gudehus M; Iqbal T; Khalif I; Marteau P; Stein J; Gasche C;
    Clin Gastroenterol Hepatol; 2013 Mar; 11(3):269-77. PubMed ID: 23078888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.
    Anker SD; Kirwan BA; van Veldhuisen DJ; Filippatos G; Comin-Colet J; Ruschitzka F; Lüscher TF; Arutyunov GP; Motro M; Mori C; Roubert B; Pocock SJ; Ponikowski P
    Eur J Heart Fail; 2018 Jan; 20(1):125-133. PubMed ID: 28436136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Responder analysis for improvement in 6-min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.
    Anker SD; Ponikowski P; Khan MS; Friede T; Jankowska EA; Fabien V; Goehring UM; Metra M; Piña IL; Coats AJS; Rosano G; Dorigotti F; Comin-Colet J; Van Veldhuisen DJ; Filippatos GS; Butler J
    Eur J Heart Fail; 2022 May; 24(5):833-842. PubMed ID: 35334136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective review of effectiveness and safety of intravenous ferric carboxymaltose given to children with iron deficiency anaemia in one UK tertiary centre.
    Tan MLN; Windscheif PM; Thornton G; Gaynor E; Rodrigues A; Howarth L
    Eur J Pediatr; 2017 Oct; 176(10):1419-1423. PubMed ID: 28844092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison between oral ferrous sulfate and intravenous ferric carboxymaltose in children with restless sleep disorder.
    DelRosso LM; Picchietti DL; Ferri R
    Sleep; 2021 Feb; 44(2):. PubMed ID: 32840615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ferric carboxymaltose in the treatment of iron deficiency in pediatric inflammatory bowel disease.
    Carman N; Muir R; Lewindon P
    Transl Pediatr; 2019 Jan; 8(1):28-34. PubMed ID: 30881896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Iron deficiency and its management in patients undergoing lipoprotein apheresis. Comparison of two parenteral iron formulations.
    Schatz U; Arneth B; Siegert G; Siegels D; Fischer S; Julius U; Bornstein SR
    Atheroscler Suppl; 2013 Jan; 14(1):115-22. PubMed ID: 23357152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
    Lyseng-Williamson KA; Keating GM
    Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients.
    Hofman JMG; Eisenga MF; Diepenbroek A; Nolte IM; van Dam B; Westerhuis R; Bakker SJL; Franssen CFM; Gaillard CAJM
    BMC Nephrol; 2018 Sep; 19(1):242. PubMed ID: 30236065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Assessment of iron deficiency anemia management in the general hospital of Grenoble: A 12-month follow-up of an intravenous ferric carboxymaltose treatment program in a cohort of patients with non-dialysis-dependent chronic kidney disease].
    Romanet T; Bedouch P; Zaoui P
    Nephrol Ther; 2019 Apr; 15(2):104-109. PubMed ID: 30803900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial.
    Khalafallah AA; Yan C; Al-Badri R; Robinson E; Kirkby BE; Ingram E; Gray Z; Khelgi V; Robertson IK; Kirkby BP
    Lancet Haematol; 2016 Sep; 3(9):e415-25. PubMed ID: 27570088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial.
    von Haehling S; Doehner W; Evertz R; Garfias-Veitl T; Derad C; Diek M; Karakas M; Birkemeyer R; Fillippatos G; Lainscak M; Butler J; Ponikowski P; Böhm M; Friede T; Anker SD
    Eur Heart J; 2024 Oct; 45(37):3789-3800. PubMed ID: 39185895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iron deficiency and safety of ferric carboxymaltose in patients with acute heart failure. AHF-ID study.
    Jacob J; Miró Ò; Ferre C; Borraz-Ordás C; Llopis-García G; Comabella R; Fernández-Cañadas JM; Mercado A; Roset A; Richard-Espiga F; Valero-Domènech A; Martínez-Gimeno JL; Martín-Sánchez FJ; Llorens P; Berrocal-Gil P; Pérez-Durá MJ; Álvarez-Pérez JM; López-Díez P; Herrero-Puente P; Comín-Colet J
    Int J Clin Pract; 2020 Oct; 74(10):e13584. PubMed ID: 32533907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous ferric carboxymaltose for the management of iron deficiency and iron deficiency anaemia in children and adolescents: a review.
    Aksan A; Zepp F; Anand S; Stein J
    Eur J Pediatr; 2022 Nov; 181(11):3781-3793. PubMed ID: 36056175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial.
    Filippatos G; Farmakis D; Colet JC; Dickstein K; Lüscher TF; Willenheimer R; Parissis J; Gaudesius G; Mori C; von Eisenhart Rothe B; Greenlaw N; Ford I; Ponikowski P; Anker SD
    Eur J Heart Fail; 2013 Nov; 15(11):1267-76. PubMed ID: 23787722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France.
    Toledano A; Luporsi E; Morere JF; Scotté F; Laribi K; Barrière J; Huot-Marchand P; Duvillié L; Concas VH; Bugat R
    Support Care Cancer; 2016 Jan; 24(1):67-75. PubMed ID: 25921449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.